Please login to the form below

Not currently logged in
Email:
Password:

Dupixent

This page shows the latest Dupixent news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

Dupixent is still too expensive despite discount, says the UK’s cost effectiveness body. ... A proposal by Sanofi to discount the cost to the NHS of its Dupixent drug for atopic dermatitis has not been enough to sway NICE, which has said it cannot back

Latest news

  • Dermira craters as acne drug fails late-stage test Dermira craters as acne drug fails late-stage test

    s IL-4 and IL-13-targeting drug Dupixent (dupilumab), Pfizer’s new topical treatment Eucrisa (crisaborole) and potentially other drugs such as GlaxoSmithKline’s asthma drug Nucala (mepolizumab), which is

  • After some big setbacks, Sanofi talks up its R&D portfolio After some big setbacks, Sanofi talks up its R&D portfolio

    antibody Praluent (alirocumab) for cholesterol-lowering, IL4 inhibitor Dupixent (dupilumab) for eczema and IL-6 blocker arthritis treatment Kevzara (sarilumab) as well as a clutch of late-stage pipeline projects - before

  • Dupixent dulls pain of diabetes slump at Sanofi Dupixent dulls pain of diabetes slump at Sanofi

    Dupixent dulls pain of diabetes slump at Sanofi. Biosimilar competition caused steep declines in its flagship product Lantus. ... Accelerating sales of Sanofi’s new atopic dermatitis drug Dupixent helped to offset steep declines in flagship diabetes

  • Sanofi, Regeneron claim EU approval for eczema drug Dupixent Sanofi, Regeneron claim EU approval for eczema drug Dupixent

    Sanofi, Regeneron claim EU approval for eczema drug Dupixent. Analysts suggest the product could be worth 5bn at peak. ... Dupixent is also being tested for its potential in nasal polyposis, another indication where it could see competition from Nucala.

  • Roche out-licenses lebrikizumab rights to Dermira Roche out-licenses lebrikizumab rights to Dermira

    Atopic dermatitis has drawn attention in pharma of late largely due to the efforts by Sanofi and Regeneron to develop their IL-4 and IL-13-targeting drug Dupixent (dupilumab) for ... methotrexate. Dupixent seems to be making a great start in the market

More from news
Approximately 9 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

Transforming healthcare through effective collaboration. Making work to feel proud of. www.dovetailstrategies.com...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics